Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) Seek FDA Approval for Boosters for Ages 16-18

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) will seek approval from the Food and Drug Administration (FDA) for a booster shot for teenagers aged 16-18 years. This announcement comes in the heels of Biden offering Americans assurance about the omicron strain of the coronavirus.

Countries omicron has affected

Experts have spotted the new mutations in South Africa, Denmark, Botswana, Canada, France, the Netherlands, Australia, Italy, Belgium, Israel, Hong Kong, Germany, and Britain. While it has still not reached the U.S, it briefly caused panic in the global markets s no one was sure of its severity. Fortunately, fears have since lessened, and stock prices have gone up.

Prized CEO Albert Bourla has come out to say that Paxlovid, an oral COVID-19 treatment, would be effective against omicron. Bourla adds that the drug could work for any mutation. Instead of targeting the virus, Paxlovid works by inviting an enzyme for viral copying. As a result, it could work against most strains. Despite this, Bourla has said that the company is making other forms of the drug in case a drug-resistant strain develops.

After a company’s study, Pfizer claims that Paxlovid is 89% effective in decreasing deaths and hospitalizations.

Pfizer confirms its new vaccine ingredient is safe 

Although Pfizer has developed vaccines and boosters that effectively treat and prevent COVID-19, misinformation continues to spread. Recently, an ingredient change in Pfizer vaccines for children has caused a lot of speculation, with some claiming that the new ingredient can stop the heart.

The ness of the vaccine includes tromethamine. Some people claim that the compound reduces blood acid and stabilizes people having a heart attack. They also speculate that it has drastic side effects such as IV thrombosis and respiratory depression. However, experts, including Pfizer and the FDA, have said that this is not true.

Experts have pointed out that tromethamine maintains the acidity in vaccines rather than stops heart attacks. For this reason, the vaccine can remain stable for longer. Furthermore, Pfizer also added it to all vaccines and not just the pediatric ones.

A study in Hungary shows that Moderna Inc (NASDAQ: MRNA) vaccines are 88.7% efficient in preventing infection and 93.6% protecting against mortality. Sputnik V has an 85.7% efficacy against infection and 93.6% against mortality.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Fiona Gibson

Fiona is a finance graduate and an expert in analyzing market trends.

Recent Stories

SignUp Now For Our Featured Newsletter